Mov­ing up the lines, As­traZeneca stakes an­oth­er PhI­II win for Lyn­parza as ad­ju­vant breast can­cer ther­a­py

As­traZeneca and Mer­ck are now fair­ly cer­tain Lyn­parza works as an ad­ju­vant ther­a­py for BR­CA-mu­tat­ed high-risk HER2-neg­a­tive ear­ly breast can­cer.

That’s be­cause the in­de­pen­dent da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER